General information about company		
Scrip code*		539872
NSE Symbol*		BAJAJHCARE
MSEI Symbol*		NOTLISTED
ISIN*		INE411U01027
Name of company		BAJAJ HEALTHCARE LIMITED
Type of company		Main Board
Class of security		Equity
Date of start of financial year		01-04-2026
Date of end of financial year		31-03-2027
Date of board meeting when results were approved		17-10-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange		09-10-2026
Description of presentation currency		INR
Level of rounding		Lakhs
Reporting Type		Quarterly
Reporting Quarter		Second quarter
Nature of report standalone or consolidated		Standalone
Whether results are audited or unaudited for the quarter ended		Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended		Unaudited
Segment Reporting		Single segment
Description of single segment		Pharmaceuticals
Start date and time of board meeting		17-10-2026 16:00
End date and time of board meeting		17-10-2026 16:24
Whether cash flow statement is applicable on company		Yes
Type of cash flow statement		Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification		Not applicable
Whether the company has any related party?		Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?		Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public		NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.		NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?		No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?		
(b) If answer to above question is No, please explain the reason for not complying.		
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?		Yes
Latest Date on which RPT policy is updated		11-02-2025
Indicate Company website link for updated RPT policy of the Company		https://www.bajajhealth.com/policies/
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?		Yes
No. of times funds raised during the quarter		1
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No	During the quarter ended 30th September 2026, there has been no default of any loan or debt securities.

Financial Results – Ind-AS

Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)	
	Date of start of reporting period	01-07-2026	01-04-2026	
	Date of end of reporting period	30-09-2026	30-09-2026	
	Whether results are audited or unaudited	Unaudited	Unaudited	
	Nature of report standalone or consolidated	Standalone	Standalone	
Part I	**Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.**			
1	**Income**			
	Revenue from operations	17590.16	34153.33	
	Other income	89.24	170.38	
	Total income	**17679.4**	**34323.71**	
2	**Expenses**			
(a)	Cost of materials consumed	9841.21	19000.12	
(b)	Purchases of stock-in-trade	0	0	
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-703.96	-1253.2	
(d)	Employee benefit expense	1911.21	3658.33	
(e)	Finance costs	597.53	1206.63	
(f)	Depreciation, depletion and amortisation expense	764.94	1466.32	
(g)	**Other Expenses**			
1	Brokerage & Commission	162.2	264.02	
2	Consumption of Stores Spares and Maintainence	434.69	1107.94	
3	Freight Forwarding & Transport	275.9	634.46	
4	Legal & Professional Expenses	228.1	403.26	
5	Material Testing & Inspection Charges	130.22	214.43	
6	Power and Fuel	791.4	1539.47	
7	Processing & Labour Charges	581.82	1162.81	
8	Provision for Credit Loss	250	350	
9	Repairs & Maintenance (Others)	94.94	148.27	
10	Others	471.61	927.43	
	Total other expenses	**3420.88**	**6752.09**	
	Total expenses	**15831.81**	**30830.29**	
3	**Total profit before exceptional items and tax**	**1847.59**	**3493.42**	
4	Exceptional items	0	0	
5	**Total profit before tax**	**1847.59**	**3493.42**	
6	**Tax expense**			
7	Current tax	0	0	
8	Deferred tax	409.61	666.16	
9	**Total tax expenses**	**409.61**	**666.16**	
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0	
11	**Net Profit Loss for the period from continuing operations**	**1437.98**	**2827.26**	
12	Profit (loss) from discontinued operations before tax	-38.19	-64.22	
13	Tax expense of discontinued operations	-9.61	-16.16	
14	**Net profit (loss) from discontinued operation after tax**	**-28.58**	**-48.06**	
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0	
16	**Total profit (loss) for period**	**1409.4**	**2779.2**	
17	Other comprehensive income net of taxes	22.45	44.9	
18	**Total Comprehensive Income for the period**	**1431.85**	**2824.1**	
19	**Total profit or loss, attributable to**			
	Profit or loss, attributable to owners of parent			
	Total profit or loss, attributable to non-controlling interests			
20	**Total Comprehensive income for the period attributable to**			
	Comprehensive income for the period attributable to owners of parent			
	Total comprehensive income for the period attributable to owners of parent non-controlling interests			
21	**Details of equity share capital**			
	Paid-up equity share capital	1683.26	1683.13	
	Face value of equity share capital	5	5	
22	Reserves excluding revaluation reserve			
23	**Earnings per share**			
i	**Earnings per equity share for continuing operations**			
	Basic earnings (loss) per share from continuing operations	4.27	8.4	
	Diluted earnings (loss) per share from continuing operations	4.26	8.38	
ii	**Earnings per equity share for discontinued operations**			
	Basic earnings (loss) per share from discontinued operations	-0.08	-0.14	
	Diluted earnings (loss) per share from discontinued operations	-0.08	-0.14	
iii	**Earnings per equity share (for continuing and discontinued operations)**			
	Basic earnings (loss) per share from continuing and discontinued operations	4.19	8.26	
	Diluted earnings (loss) per share from continuing and discontinued operations	4.18	8.24	
24	Debt equity ratio	48	48	Textual Information(1)
25	Debt service coverage ratio	226	249	Textual Information(2)
26	Interest service coverage ratio	409	390	Textual Information(3)
27	**Disclosure of notes on financial results**	**Textual Information(4)**		

Text Block	
Textual Information(1)	Debt Equity Ratio is 0.48
Textual Information(2)	DSCR is 2.49 for the half year ended 30 SEP 2026
Textual Information(3)	DSCR is 3.90 for the half year ended 30 SEP 2026
Textual Information(4)	1. The above financial results of Bajaj Healthcare Limited (the Company) have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on 17 October 2026. These results have been subjected to a limited review by the statutory auditors who have expressed an unmodified review conclusion. 2. The above un audited financial results for the quarter and half year ended 30 September 2026 have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standards (Ind AS), as prescribed under Section 133 of the Companies Act 2013 (Act) read with relevant rules issued thereunder and other accounting principles generally accepted in India in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. 3. The Company deals in pharmaceuticals products (formulations and active pharmaceutical ingredients components) which are interlinked and interdependent. Therefore, the Company has identified only one reportable segment i.e. Pharmaceuticals. 4. In the year ended 31 March 2024, the Board of Directors had approved to saledisposal of undertakingunit(s) on going concern basis, situated at plot no. N 92, L 93, T 30, MIDC Tarapur, Taluka Boisar, District Palghar, Maharashtra and vacant industrial land situated at plot no. D2CH42 and D2CH43 Dahej industrial area, GIDC, Bharuch, Gujarat (which were acquired under SARFAESI ACT, 2022 from Saraswat Bank) and plot no.E 62 and E 63 MIDC Tarapur, Taluka Boisar, District Palghar, Maharashtra. The approval of shareholders was obtained vide postal ballot. The Company has classified the assets and liabilities in relation to these units as Assets and liabilities held for saledisposal under Ind AS 105 (Non current Assets Held for Sale and Discontinued Operations). The results of the operation of these units have been presented separately on the Statement of Profit and Loss as Discontinued Operations. Out of these, one unit situated at plot no. N 92 was sold during the Quarter ended 31 March 2024 and L 93 was sold during the Quarter ended 31 March 2026. The Company has sold a portion of its Plot No. D 2CH42 and D 2CH43 Dahej Industrial Area, GIDC, Bharuch, Gujarat in the current quarter. The total value of assets classified as held for sale represents lower of carrying value or fair value. The financial information from discontinued operations: Particulars Quarter Ended Period ended Year ended 30 Sept 2026 30 June 2026 30 Sept 2025 30 Sept 2026 30 Sept 2025 31 March 2026 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) Total Income (A) 75.35 0.05 75.35 2.15 11.71 Total Expenses (B) 113.54 26.03 179.05 139.57 226.58 523.40 Loss before Tax from Discontinued Operations (C = A B) (38.19) (26.03) (179.00) (64.22) (224.43) (511.69) Tax Credit from Discontinued Operations (D) (9.61) (6.55) (45.06) (16.16) (56.49) 42.74 Loss after Tax from Discontinued Operations (E = C D) (28.58) (19.48) (133.94) (48.06) (167.94) (554.43) Subsequent to the quarter ended 30 September 2026, the Company has completed its sale of Plot No. D 2CH42 and D 2CH43 Dahej Industrial Area, GIDC, Bharuch, Gujarat. 5. On 23 June 2026, the Board of Directors of the Company approved the sale of its unit at Plot No. N 178, MIDC, Tarapur Industrial Area, Tarapur, Boisar, Palghar 401 506 with an unrelated party. The expected timeline for conclusion of Sale transaction is 31 October 2026. Hence, the unit has been classified as Property Held for Sale as at 30 September 2026. 6. During the financial year ended 31 March 2025, the Company allotted 39,84,852 equity shares and 20,79,409 convertible warrants on a preferential basis, raising an aggregate amount of Rs. 20,497.00 lakhs. The consideration for the equity shares was received in September 2024, and the shares were allotted in the same month. Further, 25 of the issue price of the convertible warrants was received in September 2024, and the balance 75 was received in March 2026. Subsequently, in March 2026, the Company approved the conversion of all 20,79,409 convertible warrants into an equivalent number of fully paid up equity shares of face value Rs. 5 each. The fund raised through allotment of equity shares and convertible warrants under the preferential issue has been utilised for following activities: Particulars Amount to be Utilised Utilised up to 30 Sept 2026 Unutilised Balance Repayment of loan 15,000.00 15,000.00 Investment in capital expenditure 3,500.00 2,912.48 587.52 General corporate purposes 1,997.00 1,993.48 3.52 Total 20,497.00 19,905.96 591.04 7. In April 2025, the Company acquired Genrx Pharmaceuticals Private Limited (in Liquidation) (Genrx), an existing company incorporated under the provisions of the Companies Act, 1956, on a going concern basis for a total consideration of Rs.1,085.00 lakhs. Subsequently, on 3 June 2025, the Company filed an application before the Honble National Company Law Tribunal (NCLT), Mumbai Bench, seeking certain reliefs and concessions necessary for the effective implementation of the acquisition and takeover of Genrx as a going concern. The said application remained pending before the NCLT as on 30 September 2026. Accordingly, Genrx has not been considered a subsidiary of the Company for consolidation purposes, as control, as defined under Ind AS 110, Consolidated Financial Statements, had not been established as at the reporting date. However, on 13 October 2026, the Company received an order from the Honble NCLT approving the acquisition of Genrx on a going concern basis. Pursuant to the aforesaid order, Genrx Pharmaceuticals Private Limited will become a wholly owned subsidiary of Bajaj Healthcare Limited, subject to the implementation of the terms and conditions specified in the order passed by the Honble NCLT and the completion of the applicable procedural and legal formalities.

Statement of Asset and Liabilities

	Particulars	Half Year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2026
	Date of end of reporting period	30-09-2026
	Whether results are audited or unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone
	Assets	
1	**Non-current assets**	
	Property, plant and equipment	22837.53
	Capital work-in-progress	1066.49
	Investment property	0
	Goodwill	0
	Other intangible assets	640.29
	Intangible assets under development	0
	Biological assets other than bearer plants	0
	Investments accounted for using equity method	0
	Non-current financial assets	
	Non-current investments	2.02
	Trade receivables, non-current	0
	Loans, non-current	0
	Other non-current financial assets	
1	Fixed deposits with remaining maturity more than 12 months	238.49
2	Amount paid for Investment in Genrx Pharma	1085
3		
4		
5		
	Details of other non-current financial assets	
	Total of other non-current financial assets	**1323.49**
	Total non-current financial assets	**1325.51**
	Deferred tax assets (net)	399.91
	Other non-current assets	
1	Capital Advances	4183.76
2	Non current tax Assets (Net)	439.91
3	Right of Use Assets	2781.12
4		
5		
	Details of other non-current assets	
	Total of other non-current assets	**7404.79**
	Total non-current assets	**33674.52**
2	**Current assets**	
	Inventories	23653.4
	Current financial asset	
	Current investments	0
	Trade receivables, current	25162.53
	Cash and cash equivalents	1347.32
	Bank balance other than cash and cash equivalents	74.67
	Loans, current	0
	Other current financial assets	
1	Advance to Staff	41.98
2	Deposits with original maturity of more than 12 months but maturing within 12 months from reporting date	196.61
3	Insurance Claim Receivable	152.35
4	Advance recoverable from related party - Genrx Pharma	191.5
5	Other Receivable	263.93
	Details of other current financial assets	
	Total of Other current financial assets	**846.37**
	Total current financial assets	**27430.89**
	Current tax assets (net)	0
	Other current assets	
1	Balance with Statutory Authority	3696.47
2	Deposit With Public Authorities and Others	795.94
3	Prepaid Expenses	1409.65
4	Advance to Suppliers	241.88
5		
	Details of other current assets	
	Total of other current assets	**6143.94**
	Total current assets	**57228.23**
3	Non-current assets classified as held for sale	7212.06
4	Regulatory deferral account debit balances and related deferred tax Assets	0
	Total assets	**98114.81**
	Equity and liabilities	
1	**Equity**	
	Equity attributable to owners of parent	
	Equity share capital	1683.26
	Other equity	54032.85
	Total equity attributable to owners of parent	**55716.11**
	Non controlling interest	
	Total equity	**55716.11**
2	**Liabilities**	
	Non-current liabilities	
	Non-current financial liabilities	
	Borrowings, non-current	7038.06
	Trade Payables, non-current	
	(A) Total outstanding dues of micro enterprises and small enterprises	0
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	0
	Total Trade payable	**0**
	Other non-current financial liabilities	
1	Lease Liabilities	1094.52
2		
3		
4		
5		
	Details of other non-current financial liabilities	
	Total of other non-current financial liabilities	**1094.52**
	Total non-current financial liabilities	**8132.58**
	Provisions, non-current	807.85
	Deferred tax liabilities (net)	0
	Deferred government grants, Non-current	0
	Other non-current liabilities	
1	Nil	0
2		
3		
4		
5		
	Details of other non-current liabilities	
	Total of other non-current liabilities	**0**
	Total non-current liabilities	**8940.43**
	Current liabilities	
	Current financial liabilities	
	Borrowings, current	19713.71
	Trade Payables, current	
	(A) Total outstanding dues of micro enterprises and small enterprises	452.56
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	10694.85
	Total Trade payable	**11147.41**
	Other current financial liabilities	
1	Employee related liability	557.29
2	Security Deposit received	30
3	Other Payables	522.89
4	Lease Liabillities	319.96
5		
	Details of other current financial liabilities	
	Total of other current financial liabilities	**1430.14**
	Total current financial liabilities	**32291.26**
	Other current liabilities	
1	Statutory Dues Payable	116.38
2		
3		
4		
5		
	Details of other current liabilities	
	Total of other current liabilities	**116.38**
	Provisions, current	32.22
	Current tax liabilities (Net)	0
	Deferred government grants, Current	0
	Total current liabilities	**32439.86**
3	Liabilities directly associated with assets in disposal group classified as held for sale	1018.41
4	Regulatory deferral account credit balances and related deferred tax liability	0
	Total liabilities	**42398.7**
	Total equity and liabilities	**98114.81**

	Disclosure of notes on assets and liabilities	

Other Comprehensive Income			
	Date of start of reporting period	01-07-2026	01-04-2026
	Date of end of reporting period	30-09-2026	30-09-2026
	Whether results are audited or unaudited	Unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]		
1	Amount of items that will not be reclassified to profit and loss		
1	Remeasurement of defined benefit plans	30.00	60.00
	Total Amount of items that will not be reclassified to profit and loss	30.00	60.00
2	Income tax relating to items that will not be reclassified to profit or loss	7.55	15.10
3	Amount of items that will be reclassified to profit and loss		
	Total Amount of items that will be reclassified to profit and loss		
4	Income tax relating to items that will be reclassified to profit or loss	0.00	0.00
5	Total Other comprehensive income	22.45	44.90

Cash flow statement, indirect

Particulars		Half Year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2026
	Date of end of reporting period	30-09-2026
	Whether results are audited or unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone
Part I	Blue color marked fields are non-mandatory.	
1	Statement of cash flows	
	Cash flows from used in operating activities	
	Profit before tax	3493.42
2	**Adjustments for reconcile profit (loss)**	
	Adjustments for finance costs	1206.63
	Adjustments for decrease (increase) in inventories	-2052.44
	Adjustments for decrease (increase) in trade receivables, current	-2153.59
	Adjustments for decrease (increase) in trade receivables, non-current	0
	Adjustments for decrease (increase) in other current assets	-1072.72
	Adjustments for decrease (increase) in other non-current assets	0
	Adjustments for other financial assets, non-current	0
	Adjustments for other financial assets, current	0
	Adjustments for other bank balances	0
	Adjustments for increase (decrease) in trade payables, current	-380.58
	Adjustments for increase (decrease) in trade payables, non-current	0
	Adjustments for increase (decrease) in other current liabilities	964.3
	Adjustments for increase (decrease) in other non-current liabilities	0
	Adjustments for depreciation and amortisation expense	1466.32
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	350
	Adjustments for provisions, current	0
	Adjustments for provisions, non-current	0
	Adjustments for other financial liabilities, current	0
	Adjustments for other financial liabilities, non-current	0
	Adjustments for unrealised foreign exchange losses gains	-118.75
	Adjustments for dividend income	0
	Adjustments for interest income	16.38
	Adjustments for share-based payments	96.63
	Adjustments for fair value losses (gains)	0
	Adjustments for undistributed profits of associates	0
	Other adjustments for which cash effects are investing or financing cash flow	0
	Other adjustments to reconcile profit (loss)	-160.1
	Other adjustments for non-cash items	0
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
	Total adjustments for reconcile profit (loss)	**-1870.68**
	Net cash flows from (used in) operations	**1622.74**
	Dividends received	0
	Interest paid	0
	Interest received	0
	Income taxes paid (refund)	54.07
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) operating activities	**1568.67**
3	**Cash flows from used in investing activities**	
	Cash flows from losing control of subsidiaries or other businesses	0
	Cash flows used in obtaining control of subsidiaries or other businesses	0
	Other cash receipts from sales of equity or debt instruments of other entities	0
	Other cash payments to acquire equity or debt instruments of other entities	0
	Other cash receipts from sales of interests in joint ventures	0
	Other cash payments to acquire interests in joint ventures	0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
	Proceeds from sales of property, plant and equipment	756.02
	Purchase of property, plant and equipment	6096.25
	Proceeds from sales of investment property	0
	Purchase of investment property	0
	Proceeds from sales of intangible assets	0
	Purchase of intangible assets	0
	Proceeds from sales of intangible assets under development	0
	Purchase of intangible assets under development	0
	Proceeds from sales of goodwill	0
	Purchase of goodwill	0
	Proceeds from biological assets other than bearer plants	0
	Purchase of biological assets other than bearer plants	0
	Proceeds from government grants	0
	Proceeds from sales of other long-term assets	0
	Purchase of other long-term assets	0
	Cash advances and loans made to other parties	0
	Cash receipts from repayment of advances and loans made to other parties	0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
	Dividends received	0
	Interest received	16.38
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0.52
	Net cash flows from (used in) investing activities	**-5323.33**
4	**Cash flows from used in financing activities**	
	Proceeds from changes in ownership interests in subsidiaries	0
	Payments from changes in ownership interests in subsidiaries	0
	Proceeds from issuing shares	0.13
	Proceeds from issuing other equity instruments	0
	Payments to acquire or redeem entity's shares	0
	Payments of other equity instruments	0
	Proceeds from exercise of stock options	0
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	4503.31
	Repayments of borrowings	1270.38
	Payments of lease liabilities	205.55
	Dividends paid	504.98
	Interest paid	1144.09
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) financing activities	**1378.44**
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	**-2376.22**
5	**Effect of exchange rate changes on cash and cash equivalents**	
	Effect of exchange rate changes on cash and cash equivalents	0
	Net increase (decrease) in cash and cash equivalents	**-2376.22**
	Cash and cash equivalents cash flow statement at beginning of period	3723.54
	Cash and cash equivalents cash flow statement at end of period	**1347.32**

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

														Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.											
Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments					
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	Notes
1	Bajaj Healthcare Limited	AABCB0103B	Mr. Sajankumar Rameshwarlal Bajaj	ADOPB0559Q	Chairman & Managing Director	Remuneration			NA			237.48	0	0										
2	Bajaj Healthcare Limited	AABCB0103B	Mr. Anil Champalal Jain	ADYPJ7000Q	Managing Director	Remuneration			NA			199.98	0	0										
3	Bajaj Healthcare Limited	AABCB0103B	Ms. Namrata Sajankumar Bajaj	AJPPB0498M	Whole-Time Director	Remuneration			NA			26.99	0	0										
4	Bajaj Healthcare Limited	AABCB0103B	Mr. Pakshal Anil Jain	BFEPJ4050H	Whole-Time Director	Remuneration			NA			27.03	0	0										
5	Bajaj Healthcare Limited	AABCB0103B	Mrs. Harshavi Pakshal Jain	BENPJ6676R	Relative of Director	Remuneration		20	Approved by the Audit Committee			9.56	0	0										
6	Bajaj Healthcare Limited	AABCB0103B	Mrs. Khushi Jain	CJAPJ8785Q	Relative of Director	Any other transaction	Legal & Professional Fees	12	Approved by the Audit Committee			3.6	1.8	0										
7	Bajaj Healthcare Limited	AABCB0103B	Mrs. Nihita Bajaj Kumar	BFJPB2052N	Relative of Director	Any other transaction	Legal & Professional Fees	24	Approved by the Audit Committee			12	0	0										
8	Bajaj Healthcare Limited	AABCB0103B	Taradevi Rameshwarlal Bajaj Charitable Trust	AABTT6237F	Charitable Trust	Any other transaction	CSR Expenses	100	Approved by the Audit Committee			0	0.33	0.33										
9	Bajaj Healthcare Limited	AABCB0103B	Genrx Pharmaceuticals Private Limited	AADCG7498N	Body corporate directly/ indirectly owned by or significantly influenced by Director/s or their relatives	Any other transaction	Operating Expenses incurred by Bajaj on behalf of Genrx Pharmaceuticals	500	Approved by the Audit Committee			87.88	103.62	191.5										
10	Bajaj Healthcare Limited	AABCB0103B	Bajaj Sindhudurg Rice Mills Limited	AAGCB3428A	Body corporate directly/ indirectly owned by or significantly influenced by Director/s or their relatives	Any other transaction	Repayment of Advance	100	Approved by the Audit Committee			10	18.52	8.52										
Total value of transaction during the reporting period												614.52												

Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)	
Mode of Fund Raising	Others
Description of mode of fund raising (Applicable in case of others is selected)	Allotment of Equity Shares pursuant to the exercise of options for conversion of convertible warrants into equity shares
Date of Raising Funds	18-03-2026
Amount Raised	5271.3
Report filed for Quarter ended	30-09-2026
Monitoring Agency	Applicable
Monitoring Agency Name, if applicable	CARE Ratings Limited
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	
If Yes, Date of shareholder Approval	
Explanation for the Deviation / Variation	Not Applicable
Comments of the Audit Committee after review	No Comments
Comments of the auditors, if any	No Comments

Sr.	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
1	Repayment & Prepayment of Secured/Unsecured Loans from Bank/NBFC in part or in full	Not Applicable	15000	15000	15000	0	
2	Investment in Capital Expenditure	Not Applicable	3500	3500	2912.48	0	
3	General Corporate Purpose	Not Applicable	2200	1997	1993.48	0	

Signatory Details	
Name of signatory	Rohan Parekh
Designation of person	Chief Financial Officer
Place	Thane
Date	17-10-2026